Prevalence and risk factors for brain white matter changes in young and middle-aged participants with Brain Dock (brain screening): a registry database study and literature review

Yamasaki, Tomohiro; Ikawa, Fusao; Hidaka, Toshikazu; Kuwabara, Masashi; Matsuda, Shingo; Ozono, Iori; Chiku, Masaaki; Kitamura, Naoyuki; Hamano, Tomoaki; Akishita, Masahiro; Yamaguchi, Shûhei; Tomimoto, Hidekazu; Suzuki, Michiyasu

doi:10.18632/aging.202933

Cited by 11 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Deshalb wird in der Bewertung der untersuchten Kohorte Bezug auf die Häufigkeit des Auftretens in der Allgemeinbevölkerung genommen. 32,33…”

Section: Patienten Und Methodikunclassified

Kombinationstherapie des Sneddon‐Syndroms zur Senkung der Inzidenz zerebrovaskulärer Komplikationen

Narwutsch,

Wohlrab,

Sperfeld

et al. 2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungHintergrundDas Sneddon‐Syndrom wird als okkludierende Vaskulopathie verstanden, die an der Haut durch eine generalisierte Livedo racemosa und im zentralen Nervensystem durch transitorische ischämische Attacken, Schlaganfälle und kognitive oder motorische Defizite klinisch evident wird. Zur Therapie werden Thrombozytenaggregationshemmer oder Antikoagulanzien empfohlen. Aufgrund der begrenzten therapeutischen Wirksamkeit und der daraus resultierenden schwerwiegenden Komplikationen schlagen wir eine Kombinationstherapie mit zusätzlichen Infusionszyklen von Alprostadil und Captopril vor und berichten über erste Langzeitergebnisse.Patienten und MethodikAlle Patienten unserer Klinik mit primärem Sneddon‐Syndrom unter Kombinationstherapie wurden im Zeitraum von 1995 bis 2020 in eine systematische retrospektive Analyse einbezogen. Die Auswertung des therapeutischen Outcomes erfolgte mittels deskriptiver Statistik im Vergleich zu historischen Kontrollgruppen, die eine Monotherapie erhalten hatten. Zudem haben wir die Ereignisrate von Komplikationen bei Unterbrechung der Kombinationstherapie analysiert.ErgebnisseWährend des Beobachtungszeitraums der Kombinationstherapie von 99,7 Patientenjahren ereignete sich keine transitorische ischämische Attacke und die Schlaganfallrate sank auf 0,02 pro Patientenjahr. Im Vergleich lagen bei den historischen Kontrollen die Raten von transitorischen ischämischen Attacken und Schlaganfällen zwischen 0,08 und 0,035 pro Patientenjahr. Nach Unterbrechung der Alprostadil‐Therapie traten bei drei Patientinnen acht Ereignisse auf.SchlussfolgerungenDie Kombinationstherapie reduziert langfristig die Inzidenz von ischämischen Ereignissen bei Patienten mit primärem Sneddon‐Syndrom.

show abstract

“…31 Deshalb wird in der Bewertung der untersuchten Kohorte Bezug auf die Häufigkeit des Auftretens in der Allgemeinbevölkerung genommen. 32,33…”

Section: Patienten Und Methodikunclassified

Kombinationstherapie des Sneddon‐Syndroms zur Senkung der Inzidenz zerebrovaskulärer Komplikationen

Narwutsch,

Wohlrab,

Sperfeld

et al. 2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…White matter lesions also occur in patients with SS and are considered a possible progression parameter 31 . Therefore, the frequency of occurrence in the general population is taken into account in the evaluation of the cohort studied 32,33 . In addition, the Montreal Cognitive Assessment (MoCA) was used to record cognitive impairments and the Modified Ranking Scale (mRS) to assess the degree of disability 34 …”

Section: Methodsmentioning

confidence: 99%

Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications

Narwutsch,

Wohlrab,

Sperfeld

et al. 2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryBackgroundSneddon syndrome is an occlusive vasculopathy that presents clinically with generalized livedo racemosa on the skin and transient ischemic attacks, strokes, and cognitive or motor deficits in the central nervous system. Antiplatelet or anticoagulant therapy is recommended. Due to the limited therapeutic efficacy and the resulting serious complications, we propose combination therapy with additional infusion cycles of alprostadil and captopril and report initial long‐term results.Patients and methodsWe performed a systematic retrospective analysis of all patients with primary Sneddon syndrome who received combination therapy in our clinic between 1995 and 2020. Therapeutic outcomes were evaluated using descriptive statistics compared to historical controls receiving monotherapy. We also analyzed the event rate of complications when combination therapy was discontinued.ResultsDuring the 99.7 patient‐years of follow‐up, there were no transient ischemic attacks and the stroke rate dropped to 0.02 per patient‐year. In comparison, the rates of transient ischemic attacks and strokes in the historical controls ranged from 0.08 to 0.035 per patient‐year. After discontinuation of alprostadil therapy, eight events occurred in three patients.ConclusionsCombination therapy reduces the long‐term incidence of ischemic events in patients with primary Sneddon syndrome.

show abstract

“…Patients who underwent a brain screening system using head MRI/A called “Brain Dock” (brain screening, SmartScan, Inc.) [ 16 ] at Medical Check Studio Tokyo Ginza and Shinjuku Clinic between June 2020 and June 2021 were included. Patients with insufficient data and in whom the COVID-19 antibody test was performed after the head MRI/A were excluded.…”

Section: Methodsmentioning

confidence: 99%

Magnetic Resonance Imaging Scan of the Brain After Mild COVID-19 Infection

Ohtake¹,

Suenaga²,

Akimoto³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

Purpose: There have been several reports of central nervous system impairments associated with severe coronavirus disease 2019 (COVID-19) infection on head magnetic resonance imaging and angiography (MRI/A). However, head MRI/A is rarely performed in mild cases, and there have been few reports on intracranial changes after COVID-19 infection in these cases. Here, we report a comparative examination of the findings seen in common head MRI/A sequences in mild cases of COVID-19.Methods: Of the 15,376 patients who underwent head MRI/A examination called "Brain Dock" between June 2020 and June 2021, 746 patients who received a COVID-19 antibody test were evaluated. Positive and negative patients were comparatively examined for head MRI/A findings such as cerebral white matter lesions, ischemic changes, cerebral microbleeds, cerebral aneurysms, arterial stenosis, sinusitis, and other abnormal findings.Results: Overall, 31 (4.2%) patients were COVID-19 positive, and all of them had mild infections not requiring hospitalization. There was no significant difference in patient characteristics and head MRI/A findings between positive and negative patients. All positive patients showed no particular abnormalities in the nasal findings such as olfactory bulb atrophy or thickening of the olfactory mucosa.Conclusion: Intracranial lesions in mild patients do not show a clear difference from those in negative patients. This indicates that findings seen in common MRI/A sequences of severe patients are not likely in mild patients, supporting that there is relatively no damage to the central nervous system in mild patients.

show abstract

Prevalence and risk factors for brain white matter changes in young and middle-aged participants with Brain Dock (brain screening): a registry database study and literature review

Cited by 11 publications

References 54 publications

Kombinationstherapie des Sneddon‐Syndroms zur Senkung der Inzidenz zerebrovaskulärer Komplikationen

Kombinationstherapie des Sneddon‐Syndroms zur Senkung der Inzidenz zerebrovaskulärer Komplikationen

Combination therapy for Sneddon syndrome to reduce the incidence of cerebrovascular complications

Magnetic Resonance Imaging Scan of the Brain After Mild COVID-19 Infection

Contact Info

Product

Resources

About